BSX

Six-month trial data show WATCHMAN FLX Pro rivals standard therapy with less bleeding.

Boston Scientific’s Q3 profit fell despite modest sales growth and new product clearances.

Belo Sun’s Volta Grande Gold Project license remains suspended pending court approval of a settlement.

Belo Sun faces renewed legal challenge to its Volta Grande project license in Brazil.

Boston Scientific reports a material cybersecurity breach with impact still under investigation.

Boston Scientific delivered strong Q2 growth, boosted buybacks, and made a major strategic investment.

Legal victory removes one hurdle, but no financial or project progress is disclosed.

This is a legal setback update, not a sign of operational or financial progress.

Belo Sun’s update is mostly future promises, not near-term value for investors.

Leadership shuffle signals uncertainty, not progress, for Belo Sun’s Brazil gold ambitions.

Legal risks remain unresolved; no financial or operational progress is demonstrated here.

This is a legal status update, not a financial or operational turning point.

Strong clinical results, but no immediate financial upside or commercial clarity for investors.

Boston Scientific’s $2B buyback is real, but the benefits are distant and modest.

Boston Scientific’s $1.5B bet on MiRus is high-risk, long-term, and mostly unproven.

This is a long-term technical milestone, not a near-term value catalyst for investors.

This is a routine event notice, not a signal of business momentum or risk.

Regulatory progress is real, but all value remains distant and unproven for TSX:BSX investors.

Boston Scientific delivers strong clinical results, but offers no financial or commercial clarity.

Boston Scientific’s sales are up, but we only see part of the financial picture.